Study of Velcade and Thalidomide in Patients With Myelodysplasia

Inclusion Criteria:

Myelodysplastic syndrome with a IPSS score of 0.5 or greater
May have had prior chemo/radiotherapy for another malignancy or myelodysplasia
ECOG performance status of 0-2
Life expectancy greater than 3 months
Total bilirubin ALT and AST Calculated creatinine clearance > 30 ml/min
Use of appropriate method of contraception during the study
ANC > 0.5 x 10(9)
Platelet count > 30 x 10(9)
Consideration of treatment with 5 azacytidine is encouraged by not required

Exclusion Criteria:

Ejection fraction < 40%
myocardial infarction within 6 months of enrollment of New York Heart Association Class III or IV heart failure, uncontrolled angina, uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
Women who are pregnant or breast-feeding
Major surgery within 4 weeks prior to enrollment
>/= grade 2 peripheral neuropathy within 14 days prior to enrollment
Uncontrolled intercurrent illness
Serious medical or psychiatric illness that could potentially interfere with the completion of treatment
Hypersensitivity to bortezomib, boron, or mannitol
Received an investigational drug within 14 days of enrollment